Search results for "GiST"

showing 10 items of 3463 documents

Prenatal Omega-6:Omega-3 Ratio and Attention Deficit and Hyperactivity Disorder Symptoms

2019

Supported by the Spanish Institute of Health Carlos III (Co-funded by European Regional Development Fund “A way to make Europe”) (CP14/00108, PI16/00261, MS14/00108 [to J.J.]), the Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya - Fons Social Europeu (2017 FI_B 00636 [to N.V-T.]), the Spanish Ministry of Science and Innovation (RYC-2012-10995 [to P.D.] and RYC-2011-08796 [to D.R.]), Obra Social Cajastur/Fundación Liberbank, Universidad de Oviedo, CIBERESP, Department of Health of the Basque Government, the Provincial Government of Gipuzkoa, the municipalities of the study area (Zumarraga, Urretxu, Legazpi, Azkoitia y Azpeitia y Beasain), Generalitat Valenciana…

MaleNeurobiologia del desenvolupamentTrastorns per dèficit d'atenció amb hiperactivitat en els infantsPediatricsmedicine.medical_specialtychildren long-chain polyunsaturated fatty acids neurodevelopment population-based cohortOffspringPopulationÀcids grassosRate ratioLogistic regressionAttention deficit disorder with hyperactivity in childrenlong-chain polyunsaturated fatty acids03 medical and health sciences0302 clinical medicinePregnancyFatty Acids Omega-6030225 pediatricsFatty Acids Omega-3medicineHumansProspective Studiespopulation-based cohortDevelopmental neurobiology030212 general & internal medicineFatty acidsChildeducationPrenatal Nutritional Physiological PhenomenaChildrenSubclinical infectionchemistry.chemical_classificationPregnancyeducation.field_of_studyneurodevelopmentbusiness.industryFetal Bloodmedicine.diseasechemistryAttention Deficit Disorder with HyperactivityDocosahexaenoic acidChild PreschoolPediatrics Perinatology and Child HealthFemalebusinessInfantsPolyunsaturated fatty acidThe Journal of Pediatrics
researchProduct

SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging☆

2008

Statistical comparisons of [(18)F]FDG PET scans between healthy subjects and patients with Alzheimer's disease (AD) or amnestic mild cognitive impairment (aMCI) using Statistical Parametric Mapping (SPM) usually require normalization of regional tracer uptake via ROIs defined using additional software. Here, we validate a simple SPM-based method for count normalization. FDG PET scans of 21 mild, 15 very mild AD, 11 aMCI patients and 15 age-matched controls were analyzed. First, we obtained relative increases in the whole patient sample compared to controls (i.e. areas relatively preserved in patients) with proportional scaling to the cerebral global mean (CGM). Next, average absolute counts…

MaleNormalization (statistics)Agingmedicine.medical_specialtyPathologyCognitive NeuroscienceLogistic regressionStatistical parametric mappingNeuroimagingAlzheimer DiseaseFluorodeoxyglucose F18Internal medicineImage Interpretation Computer-AssistedmedicineHumansDementiaHealthy agingRadionuclide ImagingCognitive impairmentAgedRetrospective StudiesBrain Mappingmedicine.diagnostic_testBrainmedicine.diseaseNeurologyPositron emission tomographyCardiologyFemaleCognition DisordersPsychologyAlgorithmsNeuroImage
researchProduct

Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuxim…

2012

Purpose To evaluate the addition of cetuximab to neoadjuvant chemotherapy before chemoradiotherapy in high-risk rectal cancer. Patients and Methods Patients with operable magnetic resonance imaging–defined high-risk rectal cancer received four cycles of capecitabine/oxaliplatin (CAPOX) followed by capecitabine chemoradiotherapy, surgery, and adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab (CAPOX+C). The primary end point was complete response (CR; pathologic CR or, in patients not undergoing surgery, radiologic CR) in patients with KRAS/BRAF wild-type tumors. Secondary end points were radiologic response (RR), progression-free survival (PFS), overall survival (OS), an…

MaleOncologyCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCetuximabKaplan-Meier Estimatemedicine.disease_causeDeoxycytidineGastroenterologyIntestinal mucosaAntineoplastic Combined Chemotherapy ProtocolsIntestinal MucosaColectomyNeoadjuvant therapyCetuximabAntibodies MonoclonalMiddle AgedCombined Modality TherapyNeoadjuvant TherapyOxaliplatinTreatment OutcomeOncologyFemaleFluorouracilKRASmedicine.drugAdultmedicine.medical_specialtyAdenocarcinomaAntibodies Monoclonal HumanizedRisk AssessmentDisease-Free SurvivalCapecitabineInternal medicinePreoperative CaremedicineHumansNeoplasm InvasivenessneoplasmsCapecitabineAgedNeoplasm StagingAnalysis of VarianceRectal Neoplasmsbusiness.industryChemoradiotherapy Adjuvantmedicine.diseaseSurvival AnalysisUnited Kingdomdigestive system diseasesOxaliplatinLogistic ModelsRadiotherapy AdjuvantbusinessChemoradiotherapyFollow-Up StudiesJournal of Clinical Oncology
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

Improvement in survival of metastatic colorectal cancer: Are the benefits of clinical trials reproduced in population-based studies?

2012

To describe trends in survival of non-resectable metastatic colorectal cancer (MCRC) over a 34-year period in a French population-based registry taking into account major advances in medical therapy.3804 patients with non-resectable metastatic colorectal cancer diagnosed between 1976 and 2009 were included. Three periods (1976-96, 1997-2004 and 2005-09) were considered.The proportion of patients receiving chemotherapy dramatically increased from 19% to 57% between the first two periods, then increased steadily thereafter reaching 59% during the last period (p0.001). Median relative survival increased from 5.9 months during the 1976-96 period to 10.2 months during the 1997-2004 period but, d…

MaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsColorectal cancermedicine.medical_treatmentPopulationAntineoplastic AgentsPopulation basedHealth Services AccessibilityInternal medicinemedicineHumansMolecular Targeted TherapyRegistriesHealthcare DisparitieseducationAgedClinical Trials as TopicChemotherapyeducation.field_of_studyEvidence-Based MedicineMedical treatmentbusiness.industryPatient SelectionPalliative CareAge FactorsTreatment optionsMiddle Agedmedicine.diseaseSurvival AnalysisSurvival RateClinical trialTreatment OutcomeOncologyFemaleFranceDiffusion of InnovationColorectal NeoplasmsbusinessMedical therapyEuropean Journal of Cancer
researchProduct

Disclosing progress in cancer survival with less delay

2019

Cancer registration plays a key role in monitoring the burden of cancer. However, cancer registry (CR) data are usually made available with substantial delay to ensure best possible completeness of case ascertainment. Here, we investigate empirically with routinely available data whether such a delay is mandatory for survival analyses or whether data can be used earlier to provide more up-to-date survival estimates. We compared distributions of prognostic factors and period relative survival estimates for three population-based CRs in Germany (Schleswig-Holstein (SH), Rhineland-Palatinate (RP), Saarland (SA)) computed on datasets extracted one (DY+1) to 5 years after the year of diagnosis (…

MaleOncologyCancer Researchmedicine.medical_specialtyTime FactorsPopulationCancer registrationEmpirical Research03 medical and health sciences0302 clinical medicineGermanyNeoplasmsInternal medicinemedicineHumansRegistrieseducationLung cancereducation.field_of_studyRelative survivalbusiness.industryCancer survivalmedicine.diseaseSurvival AnalysisCancer registryCase ascertainmentOncology030220 oncology & carcinogenesisFemalebusinessReference datasetInternational Journal of Cancer
researchProduct

Risk of thyroid as a first or second primary cancer. A population-based study in Italy, 1998–2012

2021

Abstract Background The number of patients living after a cancer diagnosis is increasing, especially after thyroid cancer (TC). This study aims at evaluating both the risk of a second primary cancer (SPC) in TC patients and the risk of TC as a SPC. Methods We analyzed two population‐based cohorts of individuals with TC or other neoplasms diagnosed between 1998 and 2012, in 28 Italian areas covered by population‐based cancer registries. Standardized incidence ratios (SIRs) of SPC were stratified by sex, age, and time since first cancer. Results A total of 38,535 TC patients and 1,329,624 patients with other primary cancers were included. The overall SIR was 1.16 (95% CI: 1.12–1.21) for SPC i…

MaleOncologyCancer Researchmedicine.medical_specialtypopulation-based cancer registriesPopulationSocio-culturaleSettore MED/42 - Igiene Generale E ApplicataHistory 21st CenturyCohort StudiesRisk FactorsProstateInternal medicinepopulation‐based cancer registriesmedicinethyroid cancerHumanscancer survivorsRadiology Nuclear Medicine and imagingRegistriesThyroid NeoplasmsOverdiagnosiseducationThyroid cancerResearch ArticlesRC254-282cancer survivors; Italy; population-based cancer registries; relative risk; second primary cancer; thyroid cancereducation.field_of_studycancer survivors Italy population-based cancer registries relative risk second primary cancer thyroid cancerbusiness.industryIncidenceIncidence (epidemiology)ThyroidNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerNeoplasms Second PrimaryHistory 20th Centurymedicine.diseaserelative riskmedicine.anatomical_structureOncologyItalyRelative riskFemalesecond primary cancerbusinessCancer PreventionResearch Article
researchProduct

Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany

2013

Risk of colorectal cancer (CRC) is considerably higher in men compared to women; however, there is inconclusive evidence of sex differences in CRC prognosis. We aimed to assess and explain sex differences in 5-year relative survival using standard and model-based period analysis among 164,996 patients diagnosed with CRC from 1997 to 2006 and reported to 11 German cancer registries covering a population of 33 million inhabitants. Age-adjusted 5-year relative survival was higher in women (64.5% vs. 61.9%, P<0.0001). A substantial survival advantage of women was confirmed in multivariate analysis after adjusting for CRC stage and subsite in subjects under 65 years of age (relative excess ri…

MaleOncologyEpidemiologyColorectal cancerlcsh:MedicineSex hormones ; Cancer detection and diagnosis ; Prognosis ; Colorectal cancer ; Rectum ; Colon ; Germany ; Age groups0302 clinical medicineGermanyRegistriesYoung adultlcsh:ScienceAged 80 and overeducation.field_of_studyMultidisciplinaryRelative survivalCancer Risk FactorsColon AdenocarcinomaAge FactorsAbsolute risk reductionMiddle Aged3. Good healthOncologyTransgender hormone therapyPopulation Surveillance030220 oncology & carcinogenesisMedicineFemale030211 gastroenterology & hepatologyColorectal NeoplasmsCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentClinical Research DesignPopulationRectal CancerYoung Adult03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansMortalityeducationBiologyRetrospective StudiesAgedNeoplasm StagingPopulation Biologybusiness.industrylcsh:RCancers and NeoplasmsCancerHormonal Causes of Cancermedicine.diseaseSurgeryLocalized diseaselcsh:QbusinessPLoS ONE
researchProduct

Cancer in Children With Fanconi Anemia and Ataxia-Telangiectasia—A Nationwide Register-Based Cohort Study in Germany

2021

PURPOSE Fanconi anemia (FA) and ataxia-telangiectasia (AT) are rare inherited syndromes characterized by abnormal DNA damage response and caused by pathogenic variants in key DNA repair proteins that are also relevant in the pathogenesis of breast cancer and other cancer types. The risk of cancer in children with these diseases is poorly understood and has never been assessed in a population-based cohort before. METHODS We identified 421 patients with FA and 160 patients with AT diagnosed between 1973 and 2020 through German DNA repair disorder reference laboratories. We linked patients' laboratory data with childhood cancer data from the German Childhood Cancer Registry. RESULTS Among 421 …

MaleOncologyRegister basedCancer Researchmedicine.medical_specialtyTime FactorsAdolescentDNA damageAnemiaDNA repairRisk AssessmentAtaxia TelangiectasiaRisk FactorsFanconi anemiaGermanyNeoplasmsInternal medicinemedicineHumansRegistriesChildbusiness.industryIncidenceAge FactorsInfantCancerPrognosismedicine.diseaseFanconi AnemiaOncologyChild PreschoolAtaxia-telangiectasiaFemalebusinessCohort studyJournal of Clinical Oncology
researchProduct

Searching for Gene Expression Differences in Primary Fibroblasts Between Patients with One and Two Neoplasms in Childhood

2012

Genetic factors are important for developing primary and subsequent malignancies in children. This study investigated the role of genetic factors involved in DNA-repair. Designed as a feasibility study, it addressed the possibility of obtaining samples for genetic analyses from former patients through the German Childhood Cancer Registry. Testing feasibility was as important as the biological question itself. We analyzed the expression of DNA-repair genes in untreated primary fibroblasts of 20 individuals with a second neoplasm compared to 20 matched single neoplasm cases using customized cDNA microarrays (1344 gene sequences, about 800 genes). Matching was by first neoplasm, age, and year …

MaleOncologymedicine.medical_specialtyAdolescentDNA RepairNeoplasmsInternal medicineGene expressionmedicineHumansNeoplasmChildGeneCells CulturedRegulation of gene expressionChildhood Cancer Registrybusiness.industryGene Expression ProfilingInfant NewbornInfantHematologyFibroblastsmedicine.diseaseCancer registryGene Expression Regulation NeoplasticGene expression profilingChildhood NeoplasmOncologyChild PreschoolPediatrics Perinatology and Child HealthImmunologyFemalebusinessPediatric Hematology and Oncology
researchProduct